Reuss, Joshua E.

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

Hwang, M., Canzoniero, J. V., Rosner, S., Zhang, G., White, J. R., Belcaid, Z., Cherry, C., Balan, A., Pereira, G., Curry, A., et al. (2022) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease Prognosis

Cited by 150

Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors

Shaikh, F. Y., Gills, J. J., Mohammad, F., White, J. R., Stevens, C. M., Ding, H., Fu, J., Tam, A., Blosser, R. L., Domingue, J. C., et al. (2022) · Cancer Immunology, Immunotherapy

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 30

A review of canakinumab and its therapeutic potential for non-small cell lung cancer

Schenk, K. M., Reuss, J. E., Choquette, K., & Spira, A. I. (2019) · Anti-Cancer Drugs

Cancer Immunotherapy and BiomarkersInflammasome and immune disorders

Cited by 22

RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).

Reuss, J. E., Gandhi, S. G., Spigel, D. R., Janne, P. A., Paz-Ares, L. G., Gadgeel, S. M., Patel, J. D., Passiglia, F., Spira, A. I., Edelman, M. J., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 7